Glycomine pulls in $12 mln Series A
San Francisco-based Glycomine, a developer of orphan drugs for serious rare monogenic disorders of metabolism, has raised $12 million in Series A financing. Sanderling Ventures led the round with participation from other investors that included Chiesi Ventures. In conjunction with the funding, Dr. Peter McWilliams, a managing director at Sanderling Ventures and Giacomo Chiesi, a managing partner at Chiesi Ventures, have been added to Glycomine's board of directors.
16 November 2016•1 min read
